Reversal Dabigatran Anticoagulant Effect With Idarucizumab
Status:
Completed
Trial end date:
2019-10-19
Target enrollment:
Participant gender:
Summary
The trial objective is to demonstrate the safety of idarucizumab, as assessed by the
occurence of patients with drug related adverse events (including immune reactions) and
all-cause mortality in paediatric venous thromboembolism patients treated with dabigatran in
ongoing clinical trials who require emergency surgery/urgent procedures or patients who have
life-threatening or uncontrolled bleeding which requires urgent intervention, when rapid
reversal of the anticoagulant effect of dabigatran is needed.